Molecular biology on the ICU. From understanding to treating sepsis

Minerva Anestesiologica

Volumn 72, Issue 5, 2006, Pages 255-267

  Winning, J ^a   Claus, R A ^a   Huse, K ^b   Bauer, Michael ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

Intensive care unit; Molecular biology; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTIINFECTIVE AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INSULIN; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM DETECTION; BLEEDING DISORDER; BLOOD CULTURE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DNA POLYMORPHISM; DRUG EFFICACY; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; HYPERCOAGULABILITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION RISK; INTENSIVE CARE UNIT; MICROBIAL ACTIVITY; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RECOMBINANT DNA TECHNOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADULT; BACTERIAL INFECTIONS; BLOOD COAGULATION DISORDERS; CHILD; CYTOKINES; ENDOTHELIUM, VASCULAR; EPITHELIUM; GENETIC PREDISPOSITION TO DISEASE; GENETIC TECHNIQUES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTENSIVE CARE; LEUKOCYTES; MOLECULAR BIOLOGY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEPSIS;

EID: 33646824357     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171:737-8.
2. Ziegeler S, Tsusaki BE, Collard CD. Influence of genotype on perioperative risk and outcome. Anesthesiology 2003;99:212-9.
3. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727-32.
4. Burt RA. Genetics of host response to malaria. Int J Parasitol 1999;29:973-9.
5. Henske EP, Short MP, Jozwiak S, Bovey CM, Ramlakhan S, Haines JL et al. Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1. Ann Hum Genet 1995;59(Pt 1):25-37.
6. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-10.
7. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999;282:561-8.
8. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78.
9. Feezor RJ, Baker HV, Xiao W, Lee WA, Huber TS, Mindrinos M et al. Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair. J Immunol 2004;172:7103-9.
10. Prucha M, Ruryk A, Boriss H, Moller E, Zazula R, Herold I et al. Expression profiling: toward an application in sepsis diagnostics. Shock 2004;22:29-33.
11. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998;280:1077-82.
12. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999;27:1330-4.
13. Marshall RP, Webb S, Hill MR, Humphries SE, Laurent GJ. Genetic polymorphisms associated with susceptibility and outcome in ARDS. Chest 2002;121:68S-9S.
14. Sutherland AM, Walley KR, Manocha S, Russell JA. The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med 2005;165:75-82.
15. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
16. Donahue BS, Gailani D, Higgins MS, Drinkwater DC, George AL, Jr. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation 2003;107:1003-8.
17. Menges T, Hermans PW, Little SG, Langefeld T, Boning O, Engel J et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001;357:1096-7.
18. Wunderink RG, Waterer GW, Cantor RM, Quasney MW. Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest 2002;121:87S.
19. Majetschak M, Obertacke U, Schade FU, Bardenheuer M, Voggenreiter G, Bloemeke B et al. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol 2002;9:1205-11.
20. O'Keefe GE, Hybki DL, Munford RS. The G - >A single nucleotide polymorphism at the -308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis after trauma. J Trauma 2002;52:817-25; discussion 825-6.
21. Tang GJ, Huang SL, Yien HW, Chen WS, Chi CW, Wu CW et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 2000;28:2733-6.
22. Majetschak M, Flohe S, Obertacke U, Schroder J, Staubach K, Nast-Kolb D et al. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 1999;230:207-14.
23. Stassen NA, Leslie-Norfleet LA, Robertson AM, Eichenberger MR, Polk HC Jr. Interferon-gamma gene polymorphisms and the development of sepsis in patients with trauma. Surgery 2002;132:289-92.
24. Gentile DA, Doyle WJ, Zeevi A, Piltcher O, Skoner DP. Cytokine gene polymorphisms moderate responses to respiratory syncytial virus in adults. Hum Immunol 2003;64:93-8.
25. Ma P, Chen D, Pan J, Du B. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002;30:1046-50.
26. Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003;58:154-6.
27. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003;31:34-8.
28. Dohmen B, Gogarten W, Kuhlen R, Rossaint R. Venous thromboembolism prophylaxis. Anaesthesist 2004;53:657-72.
29. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;68:6398-401.
30. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186:1522-5.
31. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;162:1028-32.
32. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001;29:557-61.
33. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999;353:1049-53.
34. Morimoto S, Okaishi K, Onishi M, Katsuya T, Yang J, Okuro M et al. Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients. Am J Med 2002;112:89-94.
35. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;166:646-50.
36. Harding D, Baines PB, Brull D, Vassiliou V, Ellis I, Hart A et al. Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med 2002;165:1103-6.
37. van der Pol WL, Huizinga TW, Vidarsson G, van der Linden MW, Jansen MD, Keijsers V et al. Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001;184:1548-55.
38. Bredius RG, Derkx BH, Fijen CA, de Wit TP, de Haas M, Weening RS et al. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994;170:848-53.
39. Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JG, Kuijper EJ. Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998;27:746-50.
40. Yuan FF, Wong M, Pererva N, Keating J, Davis AR, Bryant JA et al. FcgammaRIIA polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol 2003;81:192-5.
41. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:25-8.
42. Calvano JE, Um JY, Agnese DM, Hahm SJ, Kumar A, Coyle SM et al. Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients. Surg Infect (Larchmt) 2003;4:163-9.
43. Gordon AC, Lagan AL, Aganna E, Cheung L, Peters CJ, McDermott MF et al. TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immun 2004;5:631-40.
44. Balding J, Healy CM, Livingstone WJ, White B, Mynett-Johnson L, Cafferkey M et al. Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease? Genes Immun 2003;4:533-40.
45. Webb GC, Chaplin DD. Genetic variability at the human tumor necrosis factor loci. J Immunol 1990;145:1278-85.
46. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878-80.
47. Dinarello CA. Mechanism of disease: the role of interleukin-1 in disease. N Engl J Med 1993;328:744.
48. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-13.
49. van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999;13:413-26, ix.
50. Presterl E, Staudinger T, Pettermann M, Lassnigg A, Burgmann H, Winkler S et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997;156(3 Pt 1):825-32.
51. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
52. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000;275:18138-44.
53. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
54. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. The ratio of interleukin-6 to interleukin-10 correlates with severity in patients with chest and abdominal trauma. Am J Emerg Med 1999;17:548-51.
55. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-30.
56. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM et al. Protective effects of C5a blockade in sepsis. Nat Med 1999;5:788-92.
57. Lamkanfi M, Kalai M, Vandenabeele P. Caspase-12: an overview. Cell Death Differ 2004;11:365-8.
58. Hotchkiss RS, Tinsley KW, Hui JJ, Chang KC, Swanson PE, Drewry AM et al. p53-dependent and -independent pathways of apoptotic cell death in sepsis. J Immunol 2000;164:3675-80.
59. Saleh M, Vaillancourt JP, Graham RK, Huyck M, Srinivasula SM, Alnemri ES et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004;429:75-9.
60. Matsuda N, Hattori Y, Takahashi Y, Nishihira J, Jesmin S, Kobayashi M et al. Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol 2004;287:L1248-55.
61. Grassme H, Kirschnek S, Riethmueller J, Riehle A, von Kurthy G, Lang F et al. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 2000;290:527-30.
62. Chen GH, Reddy RC, Newstead MW, Tateda Y, Kyasapura BL, Standiford TJ. Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense. J Immunol 2000;165:6496-503.
63. Birukova AA, Smurova K, Birukov KG, Kaibuchi K, Garcia JG, Verin AD. Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction. Microvasc Res 2004;67:64-77.
64. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
65. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S et al.; EPWG-IBD Group; EPIMAD Group; GETAID Group. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
66. Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 2003;100: 3455-60.
67. Ahrens P, Kattner E, Kohler B, Hartel C, Seidenberg J, Segerer H et al.; Genetic Factors in Neonatology Study Group. Mutations of genes involved in the innate immune system as predictors of sepsis in very low birth weight infants. Pediatr Res 2004;55:652-6.
68. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS et al. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 1994;180:95-109.
69. Burch RM, Noronha-Blob L, Bator JM, Lowe VC, Sullivan JP. Mice treated with a leumedin or antibody to Mac-1 to inhibit leukocyte sequestration survive endotoxin challenge. J Immunol 1993;150:3397-403.
70. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71-82.
71. Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN et al. Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 1998;4:615-8.
72. Klaschik S, Lehmann LE, Raadts A, Book M, Gebel J, Hoeft A et al. Detection and differentiation of in vitro-spiked bacteria by real-time PCR and melting-curve analysis. J Clin Microbiol 2004;42:512-7.
73. Peters RP, van Agtmael MA, Danner SA, Savelkoul PH, Vandenbroucke-Grauls CM. New developments in the diagnosis of bloodstream infections. Lancet Infect Dis 2004;4:751-60.
74. de Filippis I, do Nascimento CR, Clementino MB, Sereno AB, Rebelo C, Souza NN et al. Rapid detection of Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene. Diagn Microbiol Infect Dis 2005;51:85-90.
75. Bodi M, Ardanuy C, Olona M, Castander D, Diaz E, Rello J; Department of Critical Care, Hospital Univeristari Joan XXIII, Tarragona, Spain. Therapy of ventilator-associated pneumonia: the Tarragona strategy. Clin Microbiol Infect 2001;7:32-3.
76. Marin M, Garcia de Viedma D, Ruiz-Serrano MJ, Bouza E. Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR. Antimicrob Agents Chemother 2004;48:4293-300.
77. Huletsky A, Lebel P, Picard FJ, Bernier M, Gagnon M, Boucher N et al. Identification of methicillin-resistant Staphylococcus aureus carriage in less than 1 hour during a hospital surveillance program. Clin Infect Dis 2005;40:976-81.
78. Granel B, Morange PE, Serratrice J, Ene N, Cremades S, Swiader L et al. [Heterozygous prothrombin gene mutation G20210A and associated diseases]. Rev Med Interne 2003;24:282-7.
79. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3. Erratum in: Lancet 1997;349:656.
80. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517-24.
81. Wijeratne S, Butt A, Burns S, Sherwood K, Boyd O, Swaminathan R. Cell-free plasma DNA as a prognostic marker in intensive treatment unit patients. Ann N Y Acad Sci 2004;1022:232-8.
82. Russwurm S, Deigner K, Reinhart K. Microarray technology in sepsis: tool or toy? Yearbook of Intensive Care and Emergency Health 2003:55-64.
83. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.
84. Nguyen A, Yaffe MB. Proteomics and systems biology approaches to signal transduction in sepsis. Crit Care Med 2003;31:S1-S6.
85. Kalkoff M, Cursons RT, Sleigh JW, Jacobson GM. The use of real time rtPCR to quantify inflammatory mediator expression in leukocytes from patients with severe sepsis. Anaesth Intensive Care 2004;32:746-55.
86. Mayumi T, Arishima T, Takahashi H, Takezawa J. Polymorphisms related to SIRS and inflammatory response. Nippon Rinsho 2004;62:2221-8.
87. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today 2001;6:835-9.
88. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
89. Oscarson M. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Clin Chem Lab Med 2003;41:573-80.
90. Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000;61:167-73.